Premium
Mi R ‐221 as a pre‐ and postoperative plasma biomarker for larynx cancer patients
Author(s) -
Yilmaz Seda Salman,
Guzel Esra,
Karatas Omer Faruk,
Yilmaz Mehmet,
Creighton Chad J.,
Ozen Mustafa
Publication year - 2015
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1002/lary.25332
Subject(s) - biomarker , larynx , medicine , cancer , oncology , surgery , biology , biochemistry
Objective In order to identify a plasma microRNA (miRNA) signature of larynx cancer (LCa), we examined miRNAs profile of plasma samples obtained from 30 LCa patients (preoperative and postoperative serum samples) and 30 healthy controls. Study Design Basic science research study. Methods MicroRNA profiling of eight plasma samples (four from preoperative, four from control individuals) were performed using miRNA microarray. Two of the significantly deregulated miRNAs were selected for further confirmation in the remaining samples using quantitative reverse‐transcription polymerase chain reaction (qRT‐PCR). Results Microarray profiling and qRT‐PCR analysis showed that miR‐221 was upregulated in LCa plasma samples. Further qRT‐PCR analysis demonstrated that miR‐221 was at normal levels in postoperative plasma samples. Conclusions Plasma miR‐221 may have a potential as a novel diagnostic/prognostic marker and might be considered as a therapeutic target in LCa. Level of Evidence N/A. Laryngoscope , 125:E377–E381, 2015